NYSE:HRC - Hill-Rom Stock Price, Forecast & News

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Hill-Rom declared a quarterly dividend on Friday, November 8th. Stockholders of record on Monday, December 16th will be given a dividend of $0.21 per share on Tuesday, December 31st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, December 13th. View Hill-Rom's Dividend History.

Hill-Rom Holdings, Inc. (NYSE:HRC) issued its earnings results on Friday, January, 24th. The medical technology company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The medical technology company had revenue of $685 million for the quarter, compared to analyst estimates of $684.01 million. Hill-Rom had a net margin of 5.15% and a return on equity of 21.87%. The business's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 EPS. View Hill-Rom's Earnings History.

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Hill-Rom.

Hill-Rom issued an update on its FY20 earnings guidance on Friday, January, 24th. The company provided EPS guidance of $5.50-5.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.52. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.94 billion.

3 brokerages have issued 1-year price targets for Hill-Rom's stock. Their forecasts range from $116.00 to $138.00. On average, they expect Hill-Rom's stock price to reach $127.50 in the next year. This suggests a possible upside of 16.2% from the stock's current price. View Analyst Price Targets for Hill-Rom.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

News headlines about HRC stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hill-Rom earned a news impact score of 1.4 on InfoTrie's scale. They also gave news articles about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Hill-Rom.

Hill-Rom saw a drop in short interest in January. As of January 15th, there was short interest totalling 1,620,000 shares, a drop of 12.4% from the December 31st total of 1,850,000 shares. Based on an average daily trading volume, of 392,500 shares, the short-interest ratio is presently 4.1 days. Currently, 2.4% of the shares of the company are sold short. View Hill-Rom's Current Options Chain.

Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO).

Hill-Rom's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.76%), State Street Corp (2.48%), Bank of New York Mellon Corp (1.63%), Bank of Montreal Can (1.58%), Bank of America Corp DE (1.24%) and Charles Schwab Investment Management Inc. (1.22%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

HRC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Jennison Associates LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Credit Suisse AG, Lord Abbett & CO. LLC, AQR Capital Management LLC and State Street Corp. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

HRC stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., AXA, State of New Jersey Common Pension Fund D, Acadian Asset Management LLC and UBS Group AG. View Insider Buying and Selling for Hill-Rom.

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HRC stock can currently be purchased for approximately $109.68.

Hill-Rom has a market capitalization of $7.35 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.

The official website for Hill-Rom is http://www.hill-rom.com/.

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]